SCHEMBL6888927

SCHEMBL6888927

O=c1c2cc(N3CCN4CCC3CC4)ccc2nc(-c2cccc(Cl)c2)n1C1CCC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
AVPR1A P37288 5/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRNA7 P36544 2/20 0.42
KCNH2 Q12809 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
ALOX15 P16050 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
AVPR1B P47901 2/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887263 0.91 CHRNA7 (0.43) MEN1KMT2ACHRNA7KCNH2ALOX15
SCHEMBL6888190 0.90 CHRNA7 (0.47) MEN1KMT2ACHRNA7KCNH2HRH3
SCHEMBL6888094 0.87 KDM4E (0.44) KDM4ELMNAHTTAVPR1AMEN1
SCHEMBL6886841 0.87 CHRNA7 (0.45) KMT2ACHRNA7KCNH2ALOX15GAA
SCHEMBL6887906 0.86 CHRNA7 (0.40) LMNAMEN1KMT2ACHRNA7ALOX15
SCHEMBL6888407 0.84 AVPR1A (0.43) KDM4ELMNAHTTAVPR1AMEN1
SCHEMBL6886578 0.84 AVPR1A (0.44) KDM4ELMNAHTTAVPR1AMEN1
SCHEMBL6886464 0.84 AVPR1A (0.46) AVPR1AAVPR1B
SCHEMBL1668992 0.84 ALDH1A1 (0.38) MEN1KMT2ACHRNA7HRH3ALOX15
SCHEMBL6886634 0.83 AVPR1B (0.44) AVPR1AAVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 KDM4E 2824/4885LMNA 4211/4885HTT 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.